Researchers presented favorable data on San Francisco-based Cytokinetics' fast skeletal troponin activator, CK-2127107, at the MDA Scientific Conference in Arlington, Va., held from March 19 to 22, 2017.
Here are four takeaways:
1. The ongoing Phase 2 clinical trial data shows CK-2127107 improved muscle function in mouse models with spinal muscular atrophy.
2. Researchers found single doses of CK-2127107 boosted isometric force in situ in response to sub-tetanic nerve stimulation in the mouse models.
3. CK-2127107 decreased the rate of "calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium, leading to an increase in skeletal muscle contractility."
4. Cytokinetics is working with Northbrook, Ill.-based Astellas Pharma to offer CK-2127107 as a treatment for people with SMA as well as other conditions associated with skeletal muscle weakness.